Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Key Financial Performance
Cash, cash equivalents, and short-term investments $13.9 million as of September 30, 2025, compared to $44.9 million as of December 31, 2024. The decrease is due to operational expenses, but this excludes net proceeds of approximately $94 million from a $100 million underwritten offering closed on November 5, 2025.
Cash used in operations $6.7 million for Q3 2025 compared to $16.7 million for Q3 2024, a decrease of $10 million. The reduction is attributed to lower operational costs.
Research and development expense $4 million for Q3 2025 compared to $11.1 million for Q3 2024, a decrease of $7.1 million. The decrease is primarily due to the wind-down of clinical trials for REL-1017, partially offset by increased costs for NDV-01 and sepranolone studies and an increase in R&D employees.
General and administrative expense $6.3 million for Q3 2025 compared to $11.9 million for Q3 2024, a decrease of $5.6 million. The decrease is primarily driven by reduced stock-based compensation and lower direct employee and administrative expenses.
Net loss $10.1 million for Q3 2025 compared to $21.7 million for Q3 2024, a decrease of $11.6 million. The reduction is due to lower R&D and administrative expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NDV-01 development: Reported 9-month follow-up data from Phase II study in NMIBC patients, showing a 92% overall response rate at any time with favorable safety. Secured FDA alignment on Phase III program, enabling two distinct registrational tracks. Phase III studies to begin in the first half of 2026.
Sepranolone development: Selected for Prader-Willi Syndrome (PWS) as the first clinical indication. Phase II study in PWS to start in the first half of 2026. Focused on normalizing GABA-A receptor activity to address compulsive disorders.
Market opportunity for NDV-01: Targets NMIBC, affecting 68,000 new patients annually in the U.S. and a prevalence of 744,000 patients. Potential to address high-risk and intermediate-risk NMIBC cases.
Financial position: Completed $100 million underwritten financing, providing resources to support operations into 2028. Cash, cash equivalents, and short-term investments at $13.9 million as of September 30, 2025, excluding recent financing proceeds.
Operational efficiencies: Reduced R&D expenses by $7.1 million and G&A expenses by $5.6 million in Q3 2025 compared to Q3 2024, driven by lower study costs and administrative expenses.
Strategic hires and advisory board: Appointed Dr. Raj Pruthi as Chief Medical Officer, Uro-oncology, and established a Clinical Advisory Board for NDV-01, including prominent leaders in NMIBC.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is heavily reliant on FDA approvals for its NDV-01 and sepranolone programs. Any delays or negative outcomes in regulatory discussions or approvals could significantly impact the company's ability to bring these therapies to market.
Clinical Development Risks: The success of NDV-01 and sepranolone depends on the outcomes of ongoing and future clinical trials. Any unfavorable results, such as safety concerns or lack of efficacy, could derail the programs.
Financial Risks: Although the company has secured funding to support operations into 2028, it remains dependent on external financing for long-term sustainability. Any challenges in raising additional funds could impact its ability to execute strategic plans.
Manufacturing and Supply Chain Risks: The company is in the process of transferring production to contract manufacturers for NDV-01 and sepranolone. Any delays or issues in scaling up production could affect the timelines for clinical trials and eventual commercialization.
Market Adoption Risks: Even if approved, the therapies face competitive pressures and challenges in achieving broad clinical adoption, particularly in the crowded oncology and compulsive disorder treatment markets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NDV-01 Phase III Program: Relmada plans to initiate two separate registrational studies for NDV-01 in non-muscle invasive bladder cancer (NMIBC) in the first half of 2026. The FDA has aligned on two distinct registrational paths: one for high-risk second-line BCG unresponsive NMIBC patients and another for intermediate-risk NMIBC in the adjuvant setting. The company aims to complete study design and initiate the program in early 2026.
Sepranolone Phase II Study: Relmada intends to initiate a Phase II proof-of-concept study for sepranolone in Prader-Willi Syndrome (PWS) in the first half of 2026. Preparations include engaging with the FDA on trial design and establishing a supply chain.
Financial Outlook: The company is well-capitalized following a $100 million underwritten financing, with resources to support planned operations into 2028. This includes funding for the NDV-01 registration studies and the sepranolone Phase II study.
NDV-01 Manufacturing and Supply Chain: Efforts are underway to transfer production to contract manufacturers, complete scale-up, and produce clinical batches for the NDV-01 program.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the potential market opportunities for the two indications being pursued, and what is the sequence and timeline for the studies?
A:The two indications are BCG unresponsive refractory to first-line therapy and intermediate risk NMIBC. The BCG unresponsive population is smaller, with about 8,000 patients annually, 55%-80% of whom recur after first-line therapy. The intermediate risk population is larger, with about 80,000 patients annually, half of whom may need adjuvant therapy (~40,000 patients). Both trials are planned to start in Q2 2026. For the unresponsive population, clinical data will be available by Q4 2026, with top-line data in Q2 2028. The intermediate risk study will take 15 months to enroll and 18-24 months for follow-up, with interim analysis at 70% events.
Q:What is the potential pricing for the product compared to competitors?
A:Pricing is not finalized but will be data-driven. Competitor pricing ranges from $120,000 (Zosduri) to $700,000 (Lexo) annually. The company will monitor competitor pricing and its reception by the urology community before deciding.
Q:How does the product differentiate from conventional Gemdoce, and what are the implications for market adoption?
A:Conventional Gemdoce requires specialized pharmacies and has a 4-hour procedural time, limiting its use to academic centers. The new product uses prefilled syringes, avoids specialized pharmacies, and has a 5-minute instillation time, making it more accessible for community urologists and significantly expanding the market.
Q:What is the potential impact of the BRIDGE study on the product's market opportunity?
A:The BRIDGE study compares BCG to Gemdoce in high-risk disease and will read out in two years. If Gemdoce is shown to be noninferior to BCG, it could address BCG supply issues and toxicity concerns, significantly expanding off-label use and market opportunity.
Q:Review of Unclear Management Responses
A:Management avoided providing specific pricing details, stating it was too early and dependent on future data. They also did not provide clarity on the exact impact of competitor pricing strategies on their own pricing decisions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BCG disease
CR month
Chief Medical
Clinical Advisory
FDA alignment
FDA meeting
FDA study
II study
III program
Medical Officer
NDV development
Number
Patients
Phase II
Phase III
Raj
TURBT
Type
brief
care journey
cytology
development program
element Phase
hematuria
outcome FDA
patient care
patient program
patient risk
prevalence patient
procedure
proceeds offering
program NDV
program month
receptor activity
risk NMIBC
risk line
sepranolone
setting
stage
treatment event
urine
RLMD Transcript
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call summary highlights a lack of revenue and increasing net losses, which are negative indicators. The company's operational updates and return plans were not discussed, adding uncertainty. The forward-looking statements emphasize potential risks, and the Q&A section offered no additional clarity. Although the company has sufficient funding until 2029, the increase in R&D and G&A expenses without revenue generation contributes to a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents a mixed picture: strong financial backing and strategic plans for NDV-01 and sepranolone, but with notable risks in supply chain and financial management. The Q&A section highlights uncertainties, particularly regarding compliance with FDA requirements and market adoption challenges. Despite a positive cash position and reduced R&D expenses, the increase in net loss and operational costs raises concerns. The lack of clear guidance on FDA expectations and market strategy tempers enthusiasm, leading to a neutral stock price prediction.
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
RLMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
